Les Meilleurs doctors - TOP-84 des médecins

Field of Speciality: Urology
Date of Birth: 1980
School of Medicine:  Istanbul University School of Medicine
Graduate Medical Education: University of Health Sciences Taksim Training & Research Hospital
Fellowship: Urological Oncology and Laparoscopic Urology Department of Urology SLK Kliniken Heilbronn University of Heidelberg, Germany
Foreign Language: English

Having graduated from Istanbul University, Faculty of Medicine in Istanbul, he pursued Urological Surgery residency at University of Health Sciences Taksim Training & Research Hospital, Istanbul from 2005 to 2010. He subsequently completed fellowship training in Urological Oncology and Laparoscopic Urology at Department of Urology, Heilbronn, Heidelberg University, Germany.Dr. Taş is able to provide patients curative surgery that is extremely precise, preserves sexual function, has minimal blood loss, minimal pain and quick recovery.

Firsts of Safe Urology Clinic in Turkey: Penis injections of:
Cellular derived from adipose tissue
Autologous bone marrow mesenchymal Cellular
Male-Shot

​

After graduating from Istanbul Medical Faculty in 2004, Dr. Tuncay Taş completed his specialization in Urology at Taksim Training and Research Hospital in 2010. After the training he received in 2006 and 2007 at the “Laparoscopy, Robotics and Oncology Center” of Heildelberg University, Heilbronn SLK Hospital, Germany, he continues to serve his patients in Turkey, especially in the field of Laparoscopic/Robotic Surgery. The majority of Tuncay Taş’s urology practice consists of man sexual health, cancer diagnosis and treatments

His sexual health and wellness practice offers cutting-edge technologies and treatment options for men. Dr Tas offers unique training and clinical protocols for practitioners who want to implement   Penile Implants , Penile Enhancement , SafeFill and MaleShot  into their practice. Dr Taş and his team presented the results of combined P.R.P (MALE-P-SHOT) and SVF application to the penis for the first time in Turkey at the scientific congress and shared the clinical results of these applications. It is also one of the first 5 centers in the world to publish the results of P.R.P (P.SHOT) applications. Dr Taş is one of the urology instructors at ISSCA who is fully involved in regenerative medicine.

(Source: At the congress organized by İHA International Cellular Therapies Association, Dr. Tuncay Taş shared his cell research in clinical regenerative medicine and erectile dysfunction. 2019, Sexual Medicine-Original Research2021, Apr;9(2):100313.doi:10.1016/j.esxm.2020.100313. Epub 2021 30 January.)

​

Recently Dr. Tas has developed a safe and effective treatment to improve penile circumference and has conducted training with a UK-based certification programme. This novel technique has been shown to have impressive and durable cosmetic results.

​

​

OTHER AREAS OF FOCUS

Robotic prostatectomy, Radical prostatectomy, HoLEP, Donor nephrectomy, Nephrectomy, Robotic surgery, Laparoscopic surgery, Prostate cancer, Kidney cancer, Bladder cancer, Testicular cancer, Retroperitoneal lymph node dissection for testicular cancer, Erectile dysfunction, Sexual dysfunction, Male infertility, Varicocelectomy, Male hypogonadism, Penile implant insertion, Urethroplasty, Penile reconstruction, Penile enlargement, Urethral reconstruction, Artificial urinary sphincter implantation, Bladder botox injection, Urodynamic testing, Bladder augmentation, Urinary diversion, Urethral stricture, Ureteral obstruction, HIPEC, Reconstructive surgery, Laparoscopic surgery, Fertility preservation, Minimally invasive surgery, Hypospadias

​

Membership of Scientific Organizations

Turkish Association of Urology
Turkish Medical Association
Association of Endourology
European Association of Urology
International Society for Stem Cells Applications

• Publications
https://scholar.google.com/citations?user=CA59D8UAAAAJ&hl=en

​

brief history

Graduated from Yonsei University College of Medicine

Obstetrics and Gynecology Resident at Yonsei University

Adjunct Professor, Department of Obstetrics and Gynecology, Yonsei University

Vice Director of Obstetrics and Gynecology

Co-Director of Yonsei Sarangmoa Women’s Hospital

Currently

Member of the Korean Society of Obstetrics and Gynecology

Member of the Korean Menopause Society

Member of the Korean Urogynecological Society

Member of the Korean Women's Sexual Association

Member of the Korean Society of Obstetrics and Gynecology

Member of the Korean Perinatology Association

brief history

Graduated from Chungnam National University Graduate School of Medicine

Completed internship at Gachon University Gil Hospital

Completed obstetrics and gynecology residency at Gachon University Gil Hospital

today

Regular member of the Korean Society of Obstetrics and Gynecology

Member of the Korean Society of Obstetrics and Gynecology

Korean Society of Perinatology

Korean Society of Fetal Medicine

Biographie

Le Dr Mehdi Afrit est un oncologue médical qui exerce à l'hôpital spécialisé Burjeel de Sharjah. Il possède plus de 11 ans d’expérience dans le soin et la gestion de patients atteints de cancer. Il possède une vaste expérience dans la chimiothérapie, l’hormonothérapie, l’immunothérapie et la thérapie ciblée pour les patients. Il a obtenu un certificat d'oncologie médicale de l'Institut Gustave Roussy à Paris, en France, où il a suivi une formation en chimiothérapie antitumorale et en traitement médical du cancer. De plus, il est titulaire d'un certificat international en maladies du sein. Il possède également un certificat en bonnes pratiques cliniques de Trans Celerate Biopharma Inc. et un certificat en gestion des essais cliniques : bonnes pratiques cliniques de la Faculté de médecine pharmaceutique du Collège royal des médecins. Il a auparavant travaillé pendant plus de cinq ans comme professeur adjoint d'oncologie médicale à la Faculté de médecine de Tunis. Il a ensuite exercé comme consultant, oncologue médical pendant six ans à l'hôpital Arianna en Tunisie. Il a ensuite travaillé pendant deux ans comme oncologue médical spécialisé à l'hôpital Zulekha. Il a également été chercheur dans trois essais cliniques internationaux et détient des certifications d'audit d'essais cliniques, de CRO et un certificat de formation GCP de 2016. Il est membre en règle de l'Emirates Oncology Society (EOS), de la Société européenne d'oncologie médicale (ESMO). ) et l'American Society of Clinical Oncology (ASCO). Son expertise clinique comprend, sans s'y limiter, les éléments suivants :

• Soins et traitements oncologiques pour la chimiothérapie, l'hormonothérapie, l'immunothérapie et la thérapie ciblée
• Cancer du sein
• Diagnostic de tumeur solide
• Cancer digestif
• Cancer gynécologique
• Cancer du poumon
• Cancer génito-urinaire
• Sarcome

Prix et réalisations

• Prix des Fondations Himaya et de l'Université de Sharjah

Recherche et publications

• Caractéristiques clinicopathologiques du cancer gastrique dans une cohorte de patients des pays du Conseil du Golfe : une étude transversale de 96 cas. Journal of Oncology Research Reviews & Reports Volume 2(2) : 1-3.
• Le fardeau des cancers gynécologiques aux Émirats arabes unis. Journal of Oncology Research Reviews & Reports Volume 2(4) : 1-6.
• Directives de pratique clinique du Groupe de travail sur l'oncologie des Émirats sur le dépistage du SRAS-CoV-2 chez les patients adultes asymptomatiques atteints de cancer avant un traitement anticancéreux. Journal of Oncology Research Reviews & Reports Volume 2(4) : 1-6.
• L'état des soins contre le cancer aux Émirats arabes unis en 2020 : défis et recommandations, un rapport du groupe de travail sur l'oncologie des Émirats arabes unis. Humaid Al-Shamsi, Humaa Darr, Ibrahim Abu-Gheida, Jawaher Ansari, Martine, Mehdi Afrit, Mohamad H Masri, Mohamed Abuhaleeqa. Gulf J Oncologie 2020 janvier;1(32):71-87.
• Lymphome osseux primitif : étude rétrospective multicentrique tunisienne à propos de 32 cas. Ben Ayed C, Laabidi S, Said N, Afrit M, Ben Ahmed S, Boussen H. Tunis Med. Mai 2018 ;96(5):269-272.
• Premier site de récidive après traitement adjuvant du cancer du sein à l’ère de la thérapie multimodale : quelle imagerie pour quelle patiente lors du suivi ? Nesrine M, Mehdi B, Houda EB, Soumaya L, Mehdi A, Bechir Z, Hamouda B. Breast Dis. 21 novembre 2017

Dr. Teanchai Siricharoensang spent 13 years as a senior Urologist at Samitivej Hospital Bangkok.

Having attended Siriraj medical school and Mahidol University, Dr. Chai is an Advanced laparoscopic surgeon and an endoscopic and urologist surgeon.

Certified ultrasonic lipolysis and certified anti-aging specialist and a member of the American Urological Association.